Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year

Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials